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Abstract
Background: Bipolar disorder patients frequently present recurrent episodes and often experience subsyndromal
symptoms, cognitive impairment and difficulties in functioning, with a low quality of life, illness relapses and recurrent
hospitalization. Early diagnosis and appropriate intervention may play a role in preventing neuroprogression in this
disorder. New technologies represent an opportunity to develop standardized psychological treatments using internet-
based tools that overcome some of the limitations of face-to-face treatments, in that they are readily accessible and
the timing of therapy can be tailored to user needs and availability. However, although many psychological programs
are offered through the web and mobile devices for bipolar disorder, there is a lack of high quality evidence
concerning their efficacy and effectiveness due to the great variability in measures and methodology used.
Methods: This clinical trial is a simple-blind randomized trial within a European project to compare an internet-based
intervention with treatment as usual. Bipolar disorder patients are to be included and randomly assigned to one of two
groups: 1) the experimental group (tele-care support) and 2) the control group. Participants in both groups will be
evaluated at baseline (pre-treatment) and post-treatment.
Discussion: This study describes the design of a clinical trial based on psychoeducation intervention that may have a
significant impact on both prognosis and treatment in bipolar disorder. Specifically, bringing different services together
(service aggregation), it is hoped that the approach proposed will significantly increase the impact of information and
communication technologies on access and adherence to treatment, quality of the service, patient safety, patient and
professional satisfaction, and quality of life of patients.
Trial registration: NCT02924415. Retrospectively registered 27 September 2016
Keywords: Bipolar disorder, Psychoeducation, Telemedicine
Background
Bipolar disorder patients frequently present recurrent
episodes and often experience subsyndromal symptoms,
cognitive impairment and difficulties in functioning with
a low quality of life [1–3], illness relapses and recurrent
hospitalization [4]. The number of episodes is an
important contributor to the stage progression of the
illness from less to more severe presentations and
consequently poor outcome. Therefore, early diagnosis
and appropriate intervention may play a role in preventing
neuroprogression in this disorder [5]. Pharmacological
treatments such as mood stabilizers, alone or in combin-
ation with antipsychotics, appear to be effective to
improve symptoms [6, 7]. However, patients often do not
adhere to medication and one third of them discontinue
the medication completely, increasing their number of
relapses [8]. There is evidence of the efficacy of psycho-
logical interventions as an adjunct to pharmacotherapy in
bipolar disorder to improve clinical and functional
outcomes at follow-up [9], with better adherence [10],
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prevention and delay of relapse [11, 12] and an improved
quality of life for patients [13].
The early stages of bipolar disorder is usually a crit-
ical period, and the time during which the disorder
causes the most suffering in patients and their families,
partly because of the impact the diagnosis and a lack
of knowledge about the symptoms. Early educational
interventions could increase knowledge and awareness
of the illness and treatment adherence and thereby
reduce relapses and hospitalizations [14]. Cognitive-
behavioral therapy has also proven to be effective in
the treatment of bipolar disorder [15, 16]. Other inter-
ventions such as interpersonal social rhythm therapy,
family-focused therapy and mindfulness approaches
are also indicated [9].
However there are several obstacles to the success-
ful implementation of these types of psychological
treatments. One of the major problems is the face-to-
face nature of therapy that requires the patient and
the therapist to be available at the same time. The
level of commitment required for such treatments is
difficult for many patients. Specifically, the therapy is
administered over a long period of time (e.g., 4-6
months) and the sessions take place on a fixed date
and at a fixed time (e.g., once a week, lasting 1 h).
These aspects of the treatment are associated with a
high rate of dropout, especially in more functional
patients. Moreover, to implement these intervention
programs specialized therapists are needed and there
is a gap between availability and demand [17, 18],
and hence, in many health systems, the provision of
such treatments is limited. Therefore, there is a need
to develop effective evidence-based interventions
focused on the individual characteristics of patients
allowing them to cope better with their symptoms in
a way that is feasible and cost effective for healthcare
systems [9, 12].
New information and communication technologies
represent an opportunity to develop standardized psy-
chological treatments using internet-based tools that
overcome some of the limitations of face-to-face treat-
ments, in that they are readily accessible and the timing
of therapy can be adjusted to the need and availability of
each user. Moreover, such intervention programs offer
the possibility of patients self-monitoring and continu-
ously assessing their mood (depressive and manic symp-
toms) as well as other variables such as sleep or physical
and social functioning, with two-way feedback between
patients and healthcare providers [19, 20]. This type of
intervention facilitates early intervention for subsyndro-
mal symptoms and helps patients become more aware of
their illness, manage their symptoms better and improve
their lifestyle and attitudes towards medication [21].
Nevertheless, although many online psychological
programs for bipolar disorder are offered through the
web [21–29] and mobile devices [19, 20, 30–34], there
is a lack of high quality evidence about their efficacy
and effectiveness due to the variability in measures and
methodology used [9].
Methods
Objectives
General objective
To describe the design of an online psychoeducation
treatment using new technologies and to compare its
effectiveness with standard treatment in patients with
bipolar disorder.
Specific objective
– To assess the effectiveness of a psychoeducation
treatment based on telemedicine versus usual
treatment in relation to outcomes in bipolar
disorder (patients’ illness awareness, symptoms,
functionality, relapses and rehospitalizations)
– To assess satisfaction with the treatment received
and the contact with the health service
Hypothesis
– The online treatment of bipolar disorder will be
effective for increasing awareness of the illness,
improving depressive and manic symptoms and
functionality of patients, and reducing relapses and
hospitalizations.
– Patients receiving online treatment will be more
satisfied with the treatment received and their
contact with the health service than patients
receiving the standard treatment.
Design
This is a clinical trial is a simple-blind randomized
trial within a European project titled “The Future
Internet Social and Technological Alignment
Research” (FI-STAR), to compare an internet-based
intervention with treatment as usual. This clinical trial
fulfills with the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT Checklist)
(Additional file 1).
FI-STAR provides a solution for Bipolar Patient
Treatment Management (BPTM) in the form of a plat-
form developed to support telecare of bipolar disorder
patients. The BPTM platform involves clinical profes-
sionals (psychiatrists, psychologists and psychiatric
nurses), patients and technicians connected using inter-
facing systems of the integrated multichannel service
center, OSAREAN, which was already in place prior to
this project. That is, the proposed solution for these
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patients has been developed with the internal legacy
systems of Osakidetza, the largest important health
service provider in the Basque Country.
The platform designed provides advanced communica-
tion channels and interaction tools to treat, monitor,
support and follow-up patients with bipolar disorder.
The treatment consists of online psychoeducation which
includes learning sessions (with associated assessment
questionnaires) and related psychotherapy exercises. The
participants will be able to access the psychoeducation
functionalities, whenever and from wherever they
choose, using whichever of the possible interfaces (PC,
tablet, or smartphone) they have and prefer. The psychi-
atric personnel defines the patient’s baseline parameters,
assigns assessment questionnaires for patient monitor-
ing, specifying how often they should be completed, and
sets evaluation rules to generate alerts. Both psychiatric
personnel and patients should be able to view follow-up
data (progress through the educational material, patients’
notes, changes in monitoring parameters, reported
medication intake and any side effects, event log, and
patient alerts/notifications).
Participants
Bipolar disorder patients who meet the inclusion cri-
teria are to be included and randomly assigned to
one of two treatment groups. To achieve a power of
80% to detect differences from the null hypothesis,
H0: μ1 = μ2, using a bilateral Student’s t test for two
independent samples, with a significance level of 5%,
25 patients will be included in the experimental
group (tele-care support) and 25 patients in the con-
trol group, summing to a total of 50 patients for the
study.
Inclusion criteria
– Having a diagnosis of bipolar disorder
– Being aged between 18 and 50 years
– Being in remission (in a euthymic state)
– Being familiar with current information and
communication technologies (computer, tablet
and/or smartphone)
– Being under treatment in the mental health
network of the Basque Country (Osakidetza)
Exclusion criteria
– Having hearing or literacy difficulties
– Having a diagnosis of mental retardation
– Not having access to a smartphone or other
suitable device
– Having manic or depressive symptomatology at
the time of inclusion (Hamilton Depression
Rating Scale [35, 36] > 16 and Young Mania
Rating Scale (YMRS) [37, 38] > 8)
– Having suicidal ideation
Randomization
Patients are to be randomly assigned to either a control or
an intervention group by permuted block randomization
with a block size of 4 and a 1:1 allocation using a
computer-generated random sequence. The allocation
sequence will be prepared by an independent person not
otherwise involved in the trial. The control group will
receive the standard treatment (pharmacotherapy and
regular sessions with their psychiatrist) and the inter-
vention group will receive an online psychoeducation
treatment, in addition to pharmacological treatment
prescribed by the psychiatrist.
Assessment
Patients will be assessed after being informed of the
objectives of the study and giving their informed con-
sent to participate. Data will be collected following an
assessment that will be implemented at baseline and
post-treatment (Fig. 1).
Do bipolar patients 
meet inclusion criteria?
Obtain informed 
consent
Patients excluded
RANDOMIZATION
Experimental group Control group
BASELINE ASSESSMENT
INTERVENTION 
POST-
TREATMENT 
ASSESSMENT
Online 
psychoeduction
Control group
Yes No
Fig. 1 Study procedure
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Patients are diagnosed according to the revised fourth
edition of the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-IV-TR) criteria using the Structured
Clinical Interview for DSM-IV-TR, Axis I Disorders [39].
These interviews are carried out independently by two
experienced clinicians.
Patients are also assessed with the Mood Disorder
Questionnaire [40, 41]. This instrument is a self-report
screening test for mood disorders derived from the
DSM-IV-TR criteria designed to assess symptoms of
bipolar spectrum disorder.
All patients are to be assessed at baseline and post-
treatment, in terms of depressive, manic and anxiety
symptomatology, psychosocial functioning and lifestyle
habits: diet, physical activity and sleep.
Depressive symptoms are measured with the Beck
Depression Inventory (BDI-II) [39, 40] and the Beck
Hopelessness Scale (BHS) [42, 43]. The BDI-II is a 21-
question multiple-choice self-report inventory, one of
the most widely used psychometric tests for measuring
the severity of depression [39, 40].
The BHS is a 20-item self-report inventory designed
to measure three major aspects of hopelessness: feel-
ings about the future, loss of motivation, and expect-
ation [44, 45]. Manic symptoms are assessed with the
YMRS [37, 38], an 11-item scale used to assess the
severity of this type of symptoms.
Anxiety symptoms are measured with the State-Trait
Anxiety Inventory (STAI) [46]. The STAI is composed
of 40 items with two subscales: the State Anxiety Scale
(S-Anxiety) evaluates the current state of anxiety and
the Trait Anxiety Scale (T-Anxiety) evaluates relatively
stable aspects of “anxiety proneness”.
The functioning of patients is measured using the
Functioning Assessment Short Test [47]. This is a brief
instrument designed to assess functional impairment in
severe mental disorders. The 24 items of the scale cover
6 specific areas of functioning: autonomy, occupational
functioning, cognitive functioning, financial issues, inter-
personal relationships, and leisure time.
In addition, all patients are monitored daily by collect-
ing data on the following variables: mind state, number
of hours slept, presence of stressful events, adherence
and side effects and alcohol and drug use.
Intervention program
The intervention program consists of nine sessions of on-
line psychoeducation (once a week) focused on patient
empowerment by providing specific telecare capabilities
and multi-channel communication to enable interaction
between the patients and the healthcare professionals
(psychiatrists, psychologists and psychiatric nurses).
The psychoeducation comprises learning sessions
(with associated assessment questionnaires) and related
psychotherapy exercises using their preferred interface
(i.e., PC, tablet, or smartphone).
The participants will be able to see the learning status
of each assigned learning session and access the related
multimedia content. It will be possible to download the
associated PDF documents, if participants want, but the
video content will only be available online. They will be
able to annotate material for the learning sessions and
store these notes for future consultation. Once partici-
pants have worked through the material for a given
learning session, they will have to complete and submit,
online, a specific questionnaire to assess their level of
understanding.
If the submission process fails, the system should pro-
vide appropriate feedback (process failure - subsequent
delivery attempt) to the user. If the process succeeds, the
system will evaluate the results of the assessment ques-
tionnaire, store them along with the usage parameters,
provide feedback to the user on the success of the sub-
mission process and on the results of the questionnaire,
and update the learning status of the learning session
(depending on whether they answered the questions cor-
rectly). The data collected will be stored in the BPTM
environment.
The psychotherapy exercises are ongoing activities that
require previous knowledge from the related learning
sessions. There are a range of types of exercises on
topics such as symptom detection and relapse preven-
tion. Once the related learning session has been success-
fully completed, the patients will be able to access the
related psychotherapy exercises and update them. As it
is an ongoing process, the patients will be able to access
the psychotherapy exercises over time. The new updates
will be sent and stored and the user will get feedback on
the status of the data submission process (successful or
not). Like for the learning sessions, the data collected
will be stored in the BPTM environment.
If clarification is required in relation to learning sessions
or psychotherapy exercises, the participants will be able to
interact with the psychiatric personnel through asyn-
chronous messages. The user will get feedback on the
status of the submission process (successful or not) and
the messages will be stored in the BPTM environment.
The system will also be able to, automatically, identify
potential alerts. Some examples of alert triggers are: a
patient not having started the psychoeducation process
after a certain period of time, and a patient “failing” the
assessment questionnaire more than once. Patients
should receive notifications based on their preferences
(e.g., call center call, SMS, instant messaging, or email –
to be decided). Alerts handled by the call center will be
managed through the OSAREAN platform.
The content of the nine online psychoeducation ses-
sions is as follows:
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– Session 1. What is bipolar disorder?
Information is provided to the patient about the
nature of bipolar disorder (a description of the
symptoms that characterize the disorder and
biological mechanisms involved).
– Session 2. Symptoms of the disorder
The patient is taught to identify the characteristic
symptoms of each phase of bipolar disorder.
– Session 3. Course and prognosis of the disorder
Risk factors that may contribute to worsening the
course of the disorder are explained, as are factors
related to a good prognosis.
– Session 4. Pharmacological treatment for the disorder
The mechanisms of action of medications are
explained, as are potential side effects of the
medication, in order to improve adherence and
prevent the patient stopping the medication.
– Session 5. Relapse prevention: risk and protective
factors
The patient is taught to recognize the symptoms
that precede a relapse and risk factors that increase
the likelihood of relapse, in order to improve the
course of their illness.
– Session 6. What can be done about a relapse?
It is explained to the patient that rapid identification
of the prodromal symptoms and timely intervention
can help to prevent relapse and bring him/her back
to normal.
– Session 7. Healthy lifestyle
Tips to maintain a healthy lifestyle are provided,
seeking to improve the health, quality of life,
satisfaction and happiness of the patient.
– Session 8. Toxic habits
The effect of toxic substances on the illness is
explained, to motivate the patient to avoid their use,
and thereby improve the prognosis of the illness.
– Session 9. What can I do to improve my condition?
The patient is taught how to take an active role in
their illness to improve their health and quality of life.
Statistical analysis
Outcomes in each of the groups of patients will be ana-
lyzed, to assess whether there has been clinical and/or
functional improvement, comparing between baseline
and post-treatment by T Student-test for differences in
the means of related samples.
The influence of the treatment will be analyzed com-
paring the clinical and functional improvement in each
group through an analysis of covariance (ANCOVA)
using the baseline and post-treatment scores.
Finally, logistic regression models will be built to
analyze variables potentially associated with relapses and
hospitalizations such as sleep, lifestyle, medication
adherence, side effects and adverse events.
Discussion
Telemedicine is potentially useful to complement usual
treatment, helping patients to manage their illnesses,
and helping health providers improve the care delivered,
especially by giving clinicians feedback. Nevertheless,
few randomized clinical trials have shown the effective-
ness of this approach in bipolar disorder. The random-
ized clinical trial described in this paper concerns an
internet-based psychoeducation program for bipolar dis-
order that could have a significant impact on both prog-
nosis and treatment, and may be useful for identifying
patients who need earlier and/or continuous therapeutic
interventions.
The results of our study may have a significant impact
on prognosis of bipolar disorder patients. Below, we set
out what our study seeks to accomplish and how:
 To help healthcare professionals care for as many
patients as possible and save time (for both
professionals and patients) as well as to collect data for
research, the BPTM platform will increase the
availability of psychological treatment by providing
tele-services (cheaply and with easy access), increase
the therapist’s efficiency, reduce the need for face-to-
face consultations, allow the involvement of the call
center nurses to response promptly to alerts (e.g., by
calling patients and/or caregivers) and facilitate patient
handover between doctors.
 To enhance the quality of care, improve the course of
the illness, and reduce costs to the healthcare system,
the BPTM platform will help clinicians to improve
patient follow-up (i.e., achieve closer monitoring of
symptoms, and more frequent contact with patients
including online consultations), support early
identification of risk factors to respond better to patient
needs (thereby, reducing relapses, hospitalizations and
hospital bed days, and related costs) and provide an
additional way to interact with both patients and
caregivers (namely, through secure asynchronous
messaging).
 To supply online treatment suited to each patient’s
needs, the BPTM platform will allow psychiatric
personnel to tailor patient’s treatment (e.g.,
assignation of learning sessions and questionnaires
to be completed by given users, and defining
individual patient’s baseline parameters to tune the
rules to generate alerts).
 To provide patients with a way to enhance their
knowledge about the management of their own
illness and strategies to minimize its consequences
(in particular, to reduce psychotic, anxious, manic
and depressive symptoms) and to increase their
treatment adherence, the BPTM platform will
provide access to psychoeducation and
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psychotherapy in the form of learning sessions
(including multimedia content such as video
tutorials, presentations, PDF documents and
optionally audio) and specific psychotherapy
exercises which can be performed wherever and
whenever the patient chooses (i.e., ensuring the
availability of care for busy patients).
 To enable patients to be actively involved in their
treatment process, the BPTM platform will provide a
way to monitor their status remotely by enabling the
collection of data on physiological/biometric
parameters (either manually or automatically using
sensors) and psychological parameters and images (e.g.,
photographs to identify skin problems), medication
intake, and potential medication side effects as well as
the course of the illness, by interacting with the system
through their preferred available interface (PC, tablet
or smartphone, users being asked to utilize devices they
already have available, thereby reducing costs and
promoting the sustainability of the service). Optionally
biometric data could be gathered automatically
through mobile devices by connecting to specific
biometric sensors (e.g., activity monitors, pulse
oximeters, body composition monitors).
 To allow caregivers to become more involved, increase
their knowledge about bipolar disorder and interact
with clinicians to be able to better support the care
recipients, the BPTM platform will enable their access
to specific psychoeducation-related materials and will
provide a channel of communication to interact with
the psychiatric personnel. It is envisaged that the
involvement of caregivers and/or relatives in the
treatment will reduce the patient’s acute symptoms by
stopping them developing and providing support for
early detection. Patient adherence to treatment may
also be improved by providing a better family
environment and reducing patient anxiety caused by
family disputes.
 To ensure safety, confidentially and privacy, the
BPTM platform will comply with all local
regulations and implement protocols to safeguard
the confidentiality of medical data exchanged.
 To supply user-friendly interfaces and facilitate
personalized interaction, the BPTM platform will
allow participants (i.e. patients and caregivers) to use
their preferred interface (i.e. PC, tablet or smartphone,
as available) and have a common user experience
regardless of the choice of device, and allow them to
select their preferred channels of communication for
notifications. The platform will also support well-
known interaction metaphors and usability criteria.
The limitations of this study include difficulties in the
management of the new technologies by patients,
especially the older ones or those with more cognitive im-
pairment. Likewise, the absence of face-to-face modality in
these types of interventions may decrease adherence to the
treatment due to a potential weakening of the therapeutic
relationship with the therapist and loss of associated bene-
fits. Nevertheless, combined approaches can be imple-
mented, such as using the internet-based platform with
additional support from the therapist for some patients.
In conclusion, the platform we propose may help to
improve functionality and quality of life in bipolar dis-
order, and what is most important, the act of bringing
different services together (service aggregation) might
significantly increase the impact of information and
communication technologies on access and adherence to
treatment, the quality of the service, patient safety,
patient and professional satisfaction, and quality of life
of the patients.
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